Veracyte, Inc. VCYT NASDAQ

NASDAQ Global Market • Healthcare • Biotechnology • US • USD

SharesGrow Score

72/100

4/7 Pass

SharesGrow Intrinsic Value

Il y a eu 50 transactions d'initiés récentes enregistrées pour Veracyte, Inc. (VCYT), dont 7 achats et 42 ventes. Le total des achats d'initiés s'élève à RSU Award et le total des ventes d'initiés à $11.45M.

Les initiés notables ayant une activité récente comprennent Haas Kevin Richard, Stapley Marc, Wygant Jonathan. Les transactions d'initiés peuvent fournir des indications sur la façon dont la direction perçoit la valorisation et les perspectives futures de l'action.

Transactions d'Initiés — VCYT

Date	Nom	Rôle	Type de Transaction	Actions	Prix Moyen	Valeur	Actions détenues
2026-03-24	Haas Kevin Richard	Officer	Inconnu	-	-	-	-
2026-03-06	Stapley Marc	Chief Executive Officer	Attribution de RSU	92,099	-	-	449,653
2026-03-06	Wygant Jonathan	VP, Chief Accounting Officer	Attribution de RSU	10,525	-	-	45,434
2026-03-06	Febbo Phillip G.	Chief Scientific & Med Officer	Attribution de RSU	29,603	-	-	146,949
2026-03-06	Chambers Rebecca	Chief Financial Officer	Attribution de RSU	36,181	-	-	167,377
2026-03-06	Mcguire Annie	SVP, General Counsel	Attribution de RSU	32,892	-	-	127,598
2026-03-06	Leite John	Chief Commercial Officer-clia	Attribution de RSU	36,181	-	-	143,761
2026-03-04	Stapley Marc	Chief Executive Officer	Vente Informative	26,279	$36.28	$953.37K	357,554
2026-03-04	Chambers Rebecca	Chief Financial Officer	Vente Informative	13,941	$36.33	$506.46K	131,196
2026-03-04	Mcguire Annie	SVP, General Counsel	Vente Informative	1,664	$36.34	$60.47K	94,706
2026-03-04	Leite John	Chief Commercial Officer-clia	Vente Informative	5,260	$35.19	$185.08K	107,580
2026-03-02	Stapley Marc	Chief Executive Officer	Retenue Fiscale RSU	19,455	$36.01	$700.57K	403,077
2026-03-02	Wygant Jonathan	VP, Chief Accounting Officer	Retenue Fiscale RSU	3,006	$36.01	$108.25K	34,909
2026-03-02	Febbo Phillip G.	Chief Scientific & Med Officer	Vente Informative	13,425	$36.16	$485.43K	117,346
2026-03-02	Chambers Rebecca	Chief Financial Officer	Retenue Fiscale RSU	7,234	$36.01	$260.5K	149,537
2026-03-02	Mcguire Annie	SVP, General Counsel	Retenue Fiscale RSU	6,902	$36.01	$248.54K	101,364
2026-03-02	Leite John	Chief Commercial Officer-clia	Retenue Fiscale RSU	7,517	$36.01	$270.69K	112,840
2026-02-26	Stapley Marc	Chief Executive Officer	Retenue Fiscale RSU	35,841	$38.75	$1.39M	422,532
2026-02-26	Febbo Phillip G.	Chief Scientific & Med Officer	Retenue Fiscale RSU	24,486	$38.75	$948.83K	136,806
2026-02-26	Chambers Rebecca	Chief Financial Officer	Retenue Fiscale RSU	12,049	$38.75	$466.9K	156,771
2026-02-26	Mcguire Annie	SVP, General Counsel	Retenue Fiscale RSU	10,867	$38.75	$421.1K	108,266
2026-02-26	Leite John	Chief Commercial Officer-clia	Retenue Fiscale RSU	8,905	$38.75	$345.07K	120,357
2025-12-16	Mcguire Annie	SVP, General Counsel	Vente Informative	100	$43.68	$4.37K	67,760
2025-12-05	Eastham Karin	Director	Exercice d'Options (Vente)	10,000	$7.94	$79.4K	-
2025-12-04	Stapley Marc	Chief Executive Officer	Vente Informative	3,220	$47.35	$152.46K	318,603
2025-12-04	Chambers Rebecca	Chief Financial Officer	Vente Informative	4,741	$47.25	$224.01K	109,496
2025-12-04	Mcguire Annie	SVP, General Counsel	Vente Informative	702	$47.51	$33.35K	78,499
2025-12-04	Leite John	Chief Commercial Officer-clia	Vente Informative	1,278	$47.51	$60.72K	82,113
2025-12-02	Stapley Marc	Chief Executive Officer	Retenue Fiscale RSU	7,914	$46.16	$365.31K	326,271
2025-12-02	Wygant Jonathan	VP, Chief Accounting Officer	Retenue Fiscale RSU	1,325	$46.16	$61.16K	37,420
2025-12-02	Febbo Phillip G.	Chief Scientific & Med Officer	Retenue Fiscale RSU	2,955	$46.16	$136.4K	89,486
2025-12-02	Chambers Rebecca	Chief Financial Officer	Retenue Fiscale RSU	3,384	$46.16	$156.21K	122,774
2025-12-02	Mcguire Annie	SVP, General Counsel	Retenue Fiscale RSU	3,052	$46.16	$140.88K	79,921
2025-12-02	Leite John	Chief Commercial Officer-clia	Retenue Fiscale RSU	2,900	$46.16	$133.86K	83,391
2025-11-25	Jones Evan/ Fa	Director	Vente Informative	1,106	$50.25	$55.58K	29,362
2025-11-25	Leite John	Chief Commercial Officer-clia	Vente Informative	2,808	$50.00	$140.4K	86,291
2025-11-20	Holstein Jens	Director	Vente Informative	1,460	$43.21	$63.09K	27,199
2025-11-10	Wygant Jonathan	VP, Chief Accounting Officer	Vente Informative	5,102	$42.33	$215.98K	38,745
2025-11-07	Wygant Jonathan	VP, Chief Accounting Officer	Vente Informative	5,818	$40.21	$233.93K	43,847
2025-11-05	Jones Evan/ Fa	Director	Exercice d'Options (Vente)	10,000	$5.28	$52.8K	-
2025-11-05	Eastham Karin	Director	Vente Informative	9,674	$40.02	$387.19K	13,554
2025-11-05	Chambers Rebecca	Chief Financial Officer	Vente Informative	7,000	$41.00	$287K	126,158
2025-11-05	Mcguire Annie	SVP, General Counsel	Vente Informative	6,466	$40.00	$258.64K	82,973
2025-10-28	Wygant Jonathan	VP, Chief Accounting Officer	Attribution de RSU	2,886	-	-	49,665
2025-10-06	Febbo Phillip G.	Chief Scientific & Med Officer	Vente Informative	8,349	$36.02	$300.71K	92,441
2025-10-01	Epstein Robert S	Director	Exercice d'Options (Vente)	10,000	$7.94	$79.4K	-
2025-10-01	Mcguire Annie	SVP, General Counsel	Vente Informative	2,160	$35.00	$75.61K	89,439
2025-10-01	Leite John	Chief Commercial Officer-clia	Vente Informative	2,539	$35.00	$88.87K	89,099
2025-09-19	Mcguire Annie	SVP, General Counsel	Vente Informative	2,283	$33.69	$76.92K	91,599
2025-09-04	Stapley Marc	Chief Executive Officer	Vente Informative	7,667	$30.41	$233.13K	334,185

■ Informatif — transaction sur marché ouvert (la plus significative) ■ Non informatif (achat) — récompense, exercice d'option, conversion ■ Non informatif (vente) — retenue fiscale, vente à l'acquisition ■ Neutre — don, fiducie, expiration